TG Therapeutics to Participate in the B. Riley Securities Fall 2021 Growth Biotech Best Ideas Virtual Series

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

11/09/2021 - 07:30 AM

Fireside chat scheduled for 12:00 PM ET on Thursday November 11, 2021

NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in a fireside chat during the B. Riley Securities’ Fall 2021 Growth Biotech Best Ideas Virtual Series, taking place on Thursday November 11, 2021, at 12:00 PM ET.

A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events. A replay of the webcast will be available on TG’s website following the event.

ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQ^® (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has three programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.

UKONIQ^® is a registered trademark of TG Therapeutics, Inc.

CONTACT:
	Investor Relations
	Email: ir@tgtxinc.com
	Telephone: 1.877.575.TGTX (8489), Option 4

	Media Relations:
	Email: media@tgtxinc.com
	Telephone: 1.877.575.TGTX (8489), Option 6

TG Therapeutics, Inc.

NASDAQ:TGTX

TGTX Rankings

#1856 Ranked by Market Cap

N/A Ranked by Dividends

TGTX Latest News

Apr 18, 2024

TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Apr 18, 2024

TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

Apr 15, 2024

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Mar 27, 2024

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Mar 8, 2024

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

TGTX Stock Data

Market Cap 2.06B

Float 134.88M

Insiders Ownership 9.08%

Institutions Ownership 59.26%

Short Percent 22.25%

Industry Pharmaceutical Preparation Manufacturing

Sector Manufacturing

Website Link

Country United States of America

City NEW YORK

About TGTX

tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".

Trending News